O-40 Lenalidomide inhibits proliferation of chromosome 5 mutant hematopoietic tumor cells and interferes with adaptor protein complex assembly and phosphorylation
Anita K. Gandhi(Bristol-Myers Squibb (United States)), David Stirling(University of Leeds), Anastasia Parton, S. Naziruddin, Hugh J.M. Brady(Imperial College London), Dominique Verhelle(Pfizer (United States)), Peter Schäfer(Bristol-Myers Squibb (United States))
Cited by 0
Related Papers
Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma
|Blood|2001|905
Immunomodulatory agents lenalidomide and pomalidomide co‐stimulate <scp>T</scp> cells by inducing degradation of <scp>T</scp> cell repressors <scp>I</scp> karos and <scp>A</scp> iolos via modulation of the <scp>E</scp> 3 ubiquitin ligase complex <scp>CRL</scp> 4 <scp> <sup>CRBN</sup> </scp>
|British Journal of Haematology|2013|619
The SMARCA2/4 ATPase Domain Surpasses the Bromodomain as a Drug Target in SWI/SNF-Mutant Cancers: Insights from cDNA Rescue and PFI-3 Inhibitor Studies
|Cancer Research|2015|275